Cargando…

Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach

Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Isidori, Alessandro, Loscocco, Federica, Ciciarello, Marilena, Corradi, Giulia, Lecciso, Mariangela, Ocadlikova, Darina, Parisi, Sarah, Salvestrini, Valentina, Amadori, Sergio, Visani, Giuseppe, Curti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071222/
https://www.ncbi.nlm.nih.gov/pubmed/29932105
http://dx.doi.org/10.3390/cancers10070211
_version_ 1783343834596376576
author Isidori, Alessandro
Loscocco, Federica
Ciciarello, Marilena
Corradi, Giulia
Lecciso, Mariangela
Ocadlikova, Darina
Parisi, Sarah
Salvestrini, Valentina
Amadori, Sergio
Visani, Giuseppe
Curti, Antonio
author_facet Isidori, Alessandro
Loscocco, Federica
Ciciarello, Marilena
Corradi, Giulia
Lecciso, Mariangela
Ocadlikova, Darina
Parisi, Sarah
Salvestrini, Valentina
Amadori, Sergio
Visani, Giuseppe
Curti, Antonio
author_sort Isidori, Alessandro
collection PubMed
description Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes.
format Online
Article
Text
id pubmed-6071222
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60712222018-08-09 Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach Isidori, Alessandro Loscocco, Federica Ciciarello, Marilena Corradi, Giulia Lecciso, Mariangela Ocadlikova, Darina Parisi, Sarah Salvestrini, Valentina Amadori, Sergio Visani, Giuseppe Curti, Antonio Cancers (Basel) Review Acute myeloid leukemia (AML) is a disease, which mainly affects the elderly population. Unfortunately, the prognosis of patients aged >65 years is dismal, with 1-year overall survival approaching 10% with conventional therapies. The hypothesis of harnessing the immune system against cancer, including leukemia, has been postulated for a long time, and several clinical attempts have been made in this field. In the last years, we increased our knowledge about the interplay between AML and immune cells, but no major improvement has been translated, up to now, from bench to bedside. However, the outstanding results coming from the modern immuno-oncology trials with new drugs have granted a new interest for immunotherapy in AML. Accordingly, the elderly population represents an ideal target, given the low percentage of patients eligible for allogeneic stem cell transplant. With that in mind, in the era of immunotherapy, we consider immunosenescence as the optimal background to start investigating a biology-driven approach to AML therapy in the elderly. By taking into account the physiological age-related changes of immune response, more personalized and tailored use of the new drugs and strategies harnessing the immune system against AML, has the potential to increase their efficacy and impact on clinical outcomes. MDPI 2018-06-22 /pmc/articles/PMC6071222/ /pubmed/29932105 http://dx.doi.org/10.3390/cancers10070211 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Isidori, Alessandro
Loscocco, Federica
Ciciarello, Marilena
Corradi, Giulia
Lecciso, Mariangela
Ocadlikova, Darina
Parisi, Sarah
Salvestrini, Valentina
Amadori, Sergio
Visani, Giuseppe
Curti, Antonio
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
title Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
title_full Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
title_fullStr Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
title_full_unstemmed Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
title_short Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
title_sort immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: time for a biology-driven approach
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071222/
https://www.ncbi.nlm.nih.gov/pubmed/29932105
http://dx.doi.org/10.3390/cancers10070211
work_keys_str_mv AT isidorialessandro immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT loscoccofederica immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT ciciarellomarilena immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT corradigiulia immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT leccisomariangela immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT ocadlikovadarina immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT parisisarah immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT salvestrinivalentina immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT amadorisergio immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT visanigiuseppe immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach
AT curtiantonio immunosenescenceandimmunotherapyinelderlyacutemyeloidleukemiapatientstimeforabiologydrivenapproach